Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective

Authors:

Abstract
No abstract available
Funding Information
  • Eli Lilly and Company

This publication has 25 references indexed in Scilit: